SBS 518
Alternative Names: SBS-518Latest Information Update: 10 Aug 2023
Price :
$50 *
At a glance
- Originator University of Florida
- Developer Sparian Biosciences
- Class Drug withdrawal therapies
- Mechanism of Action Dopamine plasma membrane transport protein antagonists; Sigma receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cocaine-related disorders
Most Recent Events
- 08 Aug 2023 Sparian Biosciences announces intention to submit IND to the US FDA for Cocaine-related disorders
- 08 Aug 2023 Sparian Biosciences plans a phase I trial for Cocaine-related disorders
- 21 Feb 2023 Preclinical trials in Cocaine-related disorders in USA (unspecified route) (Sparian Biosciences pipeline, February 2023)